Cardiovascular sequelae in long-term survivors of young peoples' cancer: a linked cohort study by van Laar, M et al.
promoting access to White Rose research papers
White Rose Research Online
eprints@whiterose.ac.uk
Universities of Leeds, Sheffield and York
http://eprints.whiterose.ac.uk/
This is an author produced version of a paper published in British Journal of
Cancer
White Rose Research Online URL for this paper:
http://eprints.whiterose.ac.uk/id/eprint/77801
Paper:
van Laar, M, Feltbower, RG, Gale, CP, Bowen, DT, Oliver, SE and Glaser, A
(2014) Cardiovascular sequelae in long-term survivors of young peoples' cancer:
a linked cohort study. British Journal of Cancer. 1 - 4. ISSN 0007-0920
http://dx.doi.org/10.1038/bjc.2014.37
 
 
1 
 
Cardiovascular sequelae in long term survivors of young people’s cancer – a linked 
cohort study  
Marlous van Laar
1
, Richard G. Feltbower
1
, Chris P. Gale
1,2
, David T. Bowen
3
, Steven E. 
Oliver
4,5
, Adam Glaser
6 
1
Division of Epidemiology and Biostatistics, Room 8.49, Worlsey Building, Clarendon Way, 
University of Leeds, LS2 9NL, UK.  
2
Department of Cardiology, York Teaching Hospital NHS Foundation Trust, Wigginton 
Road, York, YO31 8HE, UK. 
3
St James's Institute of Oncology, Leeds Teaching Hospitals NHS Trust, Bexley Wing, St 
James‟s University Hospital, Beckett Street, Leeds, LS9 7TF, UK.  
4
Department of Health Sciences, University of York and the Hull York Medical School, 
Seebohm Rowntree Building, Heslington, York., YO10 5DD, UK. 
5
Public Health England Knowledge and Intelligence Team (Northern and Yorkshire), Leeds 
Teaching Hospitals NHS Trust, Level 6, Bexley Wing, St James's University Hospital, 
Beckett Street, Leeds, LS9 7TF, UK.  
6
Regional Department of Paediatric Oncology and Haematology, Leeds Teaching Hospitals 
NHS Trust, Leeds General Infirmary, Great George Street, Leeds, LS1 3EX, UK.  
Corresponding Author: Dr Adam Glaser, Regional Department of Paediatric Oncology and 
Haematology, Leeds Teaching Hospitals NHS Trust, Leeds General Infirmary, Great George 
Street, Leeds, LS1 3EX, UK; email: adam.glaser@leedsth.nhs.uk; telephone: +44 (0)113 
3928779; fax: +44 (0)113  2470248 
 
Key words: Cancer, Cardiovascular, Childhood, Teenage, Survivors, Late Effects 
 
 
2 
 
ABSTRACT  
BACKGROUND: Cancer registration data (1991–2006) were linked to hospital admission 
data (1996–2011) to determine the incidence and risk of cardiovascular late effects (LEs) 
amongst long term survivors of childhood (0-14) and young adult (15-29) cancer in 
Yorkshire.   
RESULTS: Of 3,247 survivors of cancer, 3.6% had at least one cardiovascular LE. Overall, 
cardiovascular hospitalisations for the childhood cohort were 3-fold higher compared to the 
general population, but did not differ for young adults. For young adults increased rates were 
limited to „pericardial disease‟, „cardiomyopathy and heart failure‟, „pulmonary heart 
disease‟, „hypertension‟ and „conduction disorders‟.  
CONCLUSION: Survivors of childhood and young adults remain at increased risk of 
cardiovascular LEs compared to the general population.   
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INTRODUCTION  
In the UK, approximately 80% of children and young people diagnosed with a malignancy 
can expect to become a long term survivor (Cancer Research UK, 2012; Stiller, 2007). 
However, this growing cohort are at increased risk of developing chronic health conditions 
including malignant neoplasms, neurocognitive impairment and cardiotoxicity, with 
approximately two–thirds of survivors developing at least one such condition (Oeffinger et al, 
2006). Late effects (LEs) associated with survival from childhood cancer are increasingly well 
described although data reporting cardiovascular diseases identified from hospital episodes  
are limited (Blanco et al, 2011; Mulhern et al, 2004; Mulrooney et al, 2009; Neglia et al, 
2001; Travis et al, 2012; Tukenova et al, 2010; van der Pal et al, 2012), whilst issues facing 
survivors diagnosed in young adulthood are even less clearly defined (Woodward et al, 2011). 
Furthermore, information has predominantly relied on self–reported outcomes in retrospective 
cohort studies (Mulrooney et al, 2009; Oeffinger et al, 2006), rather than more objective 
measures which may be achieved by the linkage of electronic health records (Hawkins, 2010; 
Zhang et al, 2013).  
We have linked routinely collected population–based cancer registry data with administrative 
hospital admissions data, to quantify the incidence and risk of cardiovascular LEs amongst 
survivors of childhood and young adult cancer.  
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PATIENTS AND METHODS 
Case data 
The Yorkshire Specialist Register of Cancer in Children and Young People (van Laar et al, 
2010) was used to identify long term survivors (at least 5-years post diagnosis) of childhood 
and young adult cancer (0-14 and 15-29 years inclusive) diagnosed between 1991 and 2006, 
providing at least five years follow–up data. 
Hospital Admissions Data  
Cases data were linked to inpatient HES data (1996–2011) using NHS number, date of birth, 
gender and postcode, cases were also linked to outpatient HES. Inpatient HES data were 
obtained for the general population resident within Yorkshire between 1996 and 2011 and 
matched by age at hospital admission to the survivors‟ cohort in the following age–period 
groups: 5-34 years in 1996, 5-35 years in 1997, up to 5-49 years in 2011.  
Statistical Methods 
Cardiovascular LEs were grouped as follows: „hypertension‟, „cardiomyopathy; heart 
failure‟, „coronary artery disease‟, „pulmonary heart disease‟, „pericardial disease‟, „valvular 
heart disease‟, „conduction disorders‟, „cerebrovascular disease‟ and „operations and 
procedures requiring hospitalisation‟ based on ICD–10 diagnosis codes and OPCS–4.5 
procedure codes (eTable 1).  Cases were divided into two groups: those with cardiovascular 
LEs (involving at least one cardiovascular hospitalisation occurring exclusively five or more 
years post diagnosis of cancer) and those without cardiovascular LEs (either no reported LEs 
or any cardiovascular episode prior to or within five years of cancer diagnosis (occurred in 
less than 1%)).  Events were identified from all diagnosis and procedure fields, however, only 
the first occurrence of a particular event was included in the analysis so that ongoing 
conditions, which could be recorded multiple times, were not duplicated. 
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The risk of cardiovascular LEs was modelled using Royston-Parmar relative survival -  
adjusting for the risk of a cardiovascular event in the general population by attained age, year 
of event and sex (Royston & Lambert, 2006). . Explanatory variables included gender, age 
and year at diagnosis, diagnostic group, deprivation (Index of Multiple Deprivation, 
Department for Communities and Local Government (2007)) and initial treatment type. 
Further models were fitted to the following subgroups:  
i) Cases who received chemotherapy – to examine the effect of the number of different 
anthracycline drugs administered (in the absence of accurate dose information).  
ii) Cases who received radiotherapy (excluding cerebrovascular LEs) – to examine the effect 
of radiation to the chest.  
Cumulative incidence for cardiovascular LEs was estimated, treating death without 
cardiovascular LE as a competing risk. Hospitalisation rate ratios (HRR) comparing the 
survivor cohort to the general population were calculated overall and by age group using 
standardised mortality ratio techniques, and were standardised to the general population by 
single year of attained age, year of event and sex (Juul, 2006). 
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RESULTS 
Data Linkage 
A total of 3,306 met the inclusion criteria and of these 98% (n=3,247) linked to at least one 
inpatient HES record.  Outpatient records were available for 2,412 (74%) cases; however, 
99% of outpatient diagnosis codes were classified as “other and unknown causes of 
morbidity”, and were therefore not used any further.  
Cardiovascular LEs 
119 (3.6%) individuals had at least one cardiovascular LE (n=40 and 79 for 0–14 and 15–29 
year olds respectively). The cumulative incidence was 7.5% (95%CI 5.3%-10.3%) and 14.0% 
(95%CI 9.9%-18.8%) for 0-14 and 15-29 year olds respectively at 20 years from diagnosis 
(see eFigure 1). The majority of cases experienced one cardiovascular LE (70%), 15% 
experienced two and the remainder experienced between 3 and 12. The median time to 
cardiovascular LE was 10.2 years from diagnosis (IQR = 6.8 to 13.4 years) which did not 
vary by type (see eFigure 2).  
Comparison of cancer cohort to the general population 
The crude incidence of cardiovascular LEs per 10,000 person-years was higher amongst 
cancer survivors than the general population (51.29 vs. 35.19) (Table 1).  Amongst childhood 
survivors higher rates were observed for „hypertension‟ (7.8 vs. 3.0), „cardiomyopathy and 
heart failure‟ (8.4 vs. 0.9) and „cerebrovascular disease‟ (5.8 vs. 0.9). For young adult 
survivors higher incidence was observed for „cardiomyopathy and heart failure‟ (6.6 vs. 2.3) 
and „pulmonary heart disease‟ (6.06 vs. 2.83). Overall, the rate of cardiovascular 
hospitalisations was higher for the childhood cohort compared to the general population 
(HRR = 2.6, 95% CI 1.9-3.6), but not for the young adult cohort (HRR = 1.2, 95% CI 0.9–
1.5) (Figure 1). Amongst the younger cohort, there was a significant increased risk of 
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„cardiomyopathy and heart failure‟ (HRR=12.7, 95% CI 7.4-21.9), „cerebrovascular disease‟ 
(HRR=7.9, 95% CI 4.1-15.2), „pericardial disease‟ (HRR=7.9, 95% CI 3.3-19.0), 
„hypertension‟ (HRR=4.0 95% CI 2.3-7.1), „valvular heart disease‟ (HRR=3.2, 95% CI 1.0-
10.0) and „operations and procedures‟ (HRR=2.2, 95% CI 1.0-4.5). Despite no significant 
increased hospitalisation rate for young adults overall, there was a significant increase in the 
hospitalisation rate of „pericardial disease‟ (HRR=4.0, 95% CI 1.8-8.8), „cardiomyopathy and 
heart failure‟ (HRR=3.8, 95% CI 2.2-6.6), „pulmonary heart disease‟ (HRR=3.5, 95% CI 2.0-
6.4), „conduction disorders‟ (HRR=2.0, 95% CI 1.2-3.2) and „hypertension‟ (HRR=1.8, 95% 
CI 1.3-2.5) in this age group.  Results for both age groups combined are given in eTable 3. 
Predictors of cardiovascular LEs 
There was significant evidence of an increased risk of cardiovascular LEs for those diagnosed 
aged 15-29 years compared to those diagnosed aged 0-14 years in the unadjusted analysis 
(HR=1.69, P value = 0.007); no further differences in demographic and clinical variables 
were observed (eTable 2).   The excess hazard ratio of age at diagnosis in the adjusted relative 
survival model was 1.35; however, this effect was not significant (Table 2).   
There was no significant difference in the risk of cardiovascular LEs according to the number 
of anthracycline drugs administered (HR=0.56; 95% CI 0.2-1.4; P-value=0.204).   We 
observed borderline significant evidence of an increased the risk of cardiovascular LEs 
(excluding cerebrovascular disease) for those who received radiotherapy to the chest 
(HR=7.36; 95% CI 0.97–55.7; P-value=0.053) (eTables 3 and 4).
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DISCUSSION 
We report the first population based study, extending over 15 years, of cardiovascular LEs in 
survivors of childhood and young adults with cancer using person–linked electronic health 
records of specialist cancer registry and administrative hospital admission data. Notably, 
there was evidence of a significant increase in cardiovascular morbidity in survivors of 
childhood cancer compared with the general population, whilst within individuals diagnosed 
in young adulthood the increased incidence was limited to „pericardial disease‟, 
„cardiomyopathy and heart failure‟, „pulmonary heart disease‟, „conduction disorders‟ and 
„hypertension‟ compared to the general population.   
Treatment specific analysis showed an increase in the risk of cardiovascular LEs for those 
who received chest radiation which is consistent with previous studies (Mulrooney et al, 
2009; Tukenova et al, 2010). However increases in the risk of cardiovascular LEs according 
to the use and number of anthracyclines were not observed. We did not have access to 
chemotherapy and radiotherapy dose information within this study; this has recently been 
addressed by others for survivors of childhood cancer (Blanco et al, 2011; Mulrooney et al, 
2009; Tukenova et al, 2010; van der Pal et al, 2012), however, more comprehensive studies 
using accurate treatment data are still required. Furthermore, this line of enquiry should be 
extended to young adult cancer survivors in order to facilitate evidence–based risk 
stratification of follow–up and aftercare (Jefford et al, 2013). 
We undertook a bespoke patient–level linkage of clinical and administrative databases to 
study the effect of clinical exposures on long–term cardiovascular outcomes over many 
thousands of patient years.  However, the study depends on the quality of data coding which 
is likely to vary across England focus on one region may have mitigated some bias. The 
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inability to adequately interrogate outpatient data highlights a potential underestimation of 
the true size of the problem; therefore further work should concentrate on these data.  
It is important that those at risk of developing cardiovascular LEs are supported with 
strategies to maximise cardiovascular health and given access to appropriate health 
surveillance. Furthermore, all of their current and potential future health carers should be 
made aware of the specific risks for these individuals.  
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FIGURE LEGENDS 
Figure 1: Hospitalisation rate ratios and 95% confidence intervals comparing cardiovascular 
late effects amongst cancer survivors to the general population by age at diagnosis 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
13 
 
 
 
 
 
 
 
14 
 
TABLES 
Table 1: Number of cases
a 
and crude incidence per 10,000 person-years by cardiovascular category and age group 
  Age at Diagnosis
b
 
 
0–14 years  15–29 years  Total 
Category Cancer Survivors  General Population 
 
Cancer Survivors  General Population 
 
Cancer Survivors  
General 
Population 
  N (incidence)  N (incidence)  N (incidence) 
Hypertension 12 (7.75) 4009 (2.57) 
 
35 (17.68) 27293 (16.80) 
 
47 (13.32) 31580 (9.91) 
Cardiomyopathy & Heart failure 13 (8.39) 1343 (0.86) 
 
13 (6.57) 3681 (2.27) 
 
26 (7.37) 5786 (1.82) 
Operations & Procedures 7 (4.52) 3413 (2.19) 
 
18 (9.09) 11689 (7.19) 
 
25 (7.08) 21497 (6.75) 
Conduction Disorders 6 (3.87) 4740 (3.04) 
 
17 (8.59) 10664 (6.56) 
 
23 (6.52) 15790 (4.96) 
Cerebrovascular Disease 9 (5.81) 1479 (0.95) 
 
7 (3.54) 5252 (3.23) 
 
16 (4.53) 7816 (2.45) 
Pulmonary Heart Disease 3 (1.94) 1606 (1.03) 
 
12 (6.06) 4599 (2.83) 
 
15 (4.25) 5622 (1.76) 
Coronary Artery Disease 2 (1.29) 847 (0.54) 
 
12 (6.06) 10080 (6.20) 
 
14 (3.97) 17328 (5.44) 
Pericardial Disease 5 (3.23) 1386 (0.89) 
 
6 (3.03) 2592 (1.60) 
 
11 (3.12) 2661 (0.84) 
Valvular Heart Disease 3 (1.94) 1032 (0.66) 
 
1 (0.51) 1986 (1.22) 
 
4 (1.13) 4038 (1.27) 
Total
c
 60 (38.73) 19855 (12.71) 
 
121 (61.12) 77836 (47.90) 
 
181 (51.29) 112118 (35.19) 
Total Person-Years 15492.43 15613297  19796.53 16246855  35288.96 31860152 
a
For each case, multiple occurrences of the same diagnosis were not counted. 
b
Age at admission for general population corresponds to age of survivor cohort at admission dependant on their age at diagnosis.  
c
Total number of events does not equal the total number of cases as 30% of cases experienced multiple cardiovascular diagnoses. 
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Table 2: Excess hazard ratios (HR) and 95% confidence intervals (CI) obtained from a 
Royston-Parmar relative survival model, modelling the risk of a cardiovascular late event for 
long term survivors of cancer diagnosed between 1991 and 2006 aged 0–14 and 15–29 years 
inclusive. 
    95% CI   
Variable HR lower upper P value 
Sex 
    Male 1 
   Female 1.43 0.76 2.68 0.265 
Age at Diagnosis 
    0–14 1 
   15–29 1.35 0.67 2.71 0.391 
Year of Diagnosis 1.01 0.89 1.14 0.887 
Diagnostic Group 
   Other solid tumours  1 
   Leukaemia 1.97 0.81 4.76 0.132 
Lymphoma 1.49 0.60 3.68 0.389 
CNS tumours 1.55 0.56 4.28 0.394 
Treatment Group 
   Sx alone / No treatment recorded 1 
   Cx (+/– Sx) 1.23 0.58 2.63 0.592 
Rt (+/– Sx) 0.39 0.04 3.66 0.407 
Cx+RT (+/– Sx) 0.92 0.34 2.54 0.880 
Deprivation
a
 
   Most Deprived (5) 1 
     4 0.58 0.23 1.47 0.253 
  3 0.81 0.33 1.97 0.645 
  2 1.07 0.46 2.47 0.882 
Least Deprived (1) 0.35 0.05 2.31 0.274 
a
Index of Multiple Deprivation 2007 
   
 
 
 
 
 
 
 
 
 
 
